Category: Advances in LLM
High-Dose Cytarabine in Mantle Cell Lymphoma
Peter Martin, MD Assistant Professor of Medicine Department of Hematology Weill Cornell Medical College Cornell University New York, New York H&O What are the current high-intensity […]
FLT3 Inhibitors for Acute Myeloid Leukemia
Jeffrey E. Lancet, MD Senior Member and Professor of Oncologic Sciences Moffitt Cancer Center University of South Florida College of Medicine Tampa, Florida H&O What […]
Chemotherapy-Free Treatment of Acute Promyelocytic Leukemia
Clinical Advances in Hematology & Oncology August 2015, Volume 13, Issue 8 Farhad Ravandi, MD Professor of Medicine Chief of the Section of Developmental Therapeutics […]
Managing Primary Central Nervous System Lymphoma
Clinical Advances in Hematology & Oncology July 2015, Volume 13, Issue 7 Tracy Batchelor, MD, MPH Executive Director Stephen E. and Catherine Pappas Center for […]
New Therapies for Polycythemia Vera
Volume 13, Issue 6 June 2015 Srdan Verstovsek, MD, PhD Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center […]
Monitoring Lymphoma Patients After Therapy
Clinical Advances in Hematology & Oncology May 2015, Volume 13, Issue 5 Mark Roschewski, MD Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland […]
New Developments in Richter Syndrome
Clinical Advances in Hematology & Oncology April 2015, Volume 13, Issue 4 New Developments in Richter Syndrome Nitin Jain, MD, Assistant Professor, Department of Leukemia, […]
Rituximab Maintenance in Follicular Lymphoma
Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Paul M. Barr, MD, Assistant Professor, Department of Medicine, University of Rochester, Medical Center, Rochester, New York […]
Evolving Treatments in Acute Myeloid Leukemia
Clinical Advances in Hematology & Oncology February 2015, Volume 13, Issue 2 Gail J. Roboz, MD, Associate Professor of Medicine, Weill Medical College of Cornell University, New York […]
In Situ Vaccination as a Therapy for Low-Grade Lymphoma
Joshua Brody, MD, Assistant Professor of Medicine, Department of Hematology and Medical Oncology, Mount Sinai Medical Center, New York, New York H&O How can in situ vaccination improve upon standard […]
Idelalisib for Chronic Lymphocytic Leukemia
Clinical Advances in Hematology & Oncology December 2014, Volume 12, Issue 12 Jennifer R. Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard […]
Dose-Adjusted EPOCH-R for Burkitt Lymphoma
Clinical Advances in Hematology & Oncology November 2014, Volume 12, Issue 11 Dieter Hoelzer, MD, Professor of Medicine and Hematology, Goethe University Hospital, Frankfurt, Germany H&O What […]
ABT-199 for Chronic Lymphocytic Leukemia
Clinical Advances in Hematology & Oncology October 2014, Volume 12, Issue 10 John Seymour, MD Professor, Director, Cancer Medicine, Peter MacCallum Cancer Centre, Victoria, Australia H&O What […]
R2-CHOP vs R-CHOP for Diffuse Large B-Cell Lymphoma
Clinical Advances in Hematology & Oncology September 2014, Volume 12, Issue 9 Nathan H. Fowler, MD, Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer […]
New Antibodies for Acute Lymphocytic Leukemia
Clinical Advances in Hematology & Oncology August 2014, Volume 12, Issue 8 Anjali S. Advani, MD Associate Professor, Departments of Hematology and Oncology, & Translational Hematology and Oncology […]
Switching Drugs Midstream for Patients With Chronic Myeloid Leukemia
July 2014, Volume 12, Issue 7 Daniel J. DeAngelo, MD, PhD Associate Professor of Medicine, Harvard Medical School, Department of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts H&O Have concrete […]
The Use of Obinutuzumab in Chronic Lymphocytic Leukemia
Clinical Advances in Hematology & Oncology June 2014, Volume 12, Issue 6 William Wierda, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD […]
The Current Status of Ponatinib in the Treatment of Chronic Myeloid Leukemia
Clinical Advances in Hematology & Oncology May 2014, Volume 12, Issue 5 Michael Deininger, MD, PhD Chief Division of Hematology and Hematologic Malignancies M.M. Wintrobe Professor […]
Treating Myelodysplastic Syndrome When Hypomethylating Agents Stop Working
Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 Elias Jabbour, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson […]
Update on Proteasome Inhibitors in Multiple Myeloma
Clinical Advances in Hematology & Oncology March 2014, Volume 12, Issue 3 Paul G. Richardson, MD R.J. Corman Professor of Medicine, Harvard Medical School, Director of Clinical Research, Clinical Program […]